Transgene SA (0OCQ.L)
| Previous close | 2.2600 |
| Open | 2.3400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.3300 - 2.3400 |
| 52-week range | 2.3300 - 2.3400 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 145.331M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3260 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
STRASBOURG, France, May 27, 2022--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The conference will be held online and in-person in Chica
- Business Wire
Transgene’s Combined General Meeting of May 25, 2022
STRASBOURG, France, May 25, 2022--Regulatory News: The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France).
- Business Wire
Transgene Announces Upcoming Investor Meetings
STRASBOURG, France, May 17, 2022--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will participate in the upcoming investor events set out below:
